Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Marshall

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry Letters|May 20, 2018
Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11Matthew W Martin, Jennifer Y Lee, David R Lancia, et al.
Experimental Hematology|November 16, 2024
FT-4202, a selective pyruvate kinase R activator for sickle cell diseaseAnna Ericsson, David J Richard, Erik Wilker, et al.
Biochemical Pharmacology|May 6, 2009
An inhibitor of Janus kinase 2 prevents polycythemia in miceAnjili Mathur, Jan-Rung Mo, Manfred Kraus, et al.
Research Square|February 27, 2024
Targeting <i>CCNE1</i> amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATRHaineng Xu, Erin George, David Gallo, et al.
Journal of Medicinal Chemistry|September 28, 2011
Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disordersJongwon Lim, Brandon Taoka, Ryan D Otte, et al.
The Journal of Trauma and Acute Care Surgery|March 26, 2014
A community traffic safety analysis of pedestrian and bicyclist injuries based on the catchment area of a trauma centerDekeya R Slaughter, Nick Williams, Stephen P Wall, et al.
Cancer Research|August 26, 2024
Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast CancerMi Li, Amriti R Lulla, Yan Wang, et al.
Nature Communications|April 1, 2025
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATRHaineng Xu, Erin George, David Gallo, et al.
Nutrients|January 10, 2026
The Responsible Health AI Readiness and Maturity Index (RHAMI): Applications for a Global Narrative Review of Leading AI Use Cases in Public Health NutritionDominique J Monlezun, Gary Marshall, Lillian Omutoko, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|May 20, 2018
Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11Matthew W Martin, Jennifer Y Lee, David R Lancia, et al.
Experimental Hematology|November 16, 2024
FT-4202, a selective pyruvate kinase R activator for sickle cell diseaseAnna Ericsson, David J Richard, Erik Wilker, et al.
Biochemical Pharmacology|May 6, 2009
An inhibitor of Janus kinase 2 prevents polycythemia in miceAnjili Mathur, Jan-Rung Mo, Manfred Kraus, et al.
Research Square|February 27, 2024
Targeting <i>CCNE1</i> amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATRHaineng Xu, Erin George, David Gallo, et al.
Journal of Medicinal Chemistry|September 28, 2011
Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disordersJongwon Lim, Brandon Taoka, Ryan D Otte, et al.
The Journal of Trauma and Acute Care Surgery|March 26, 2014
A community traffic safety analysis of pedestrian and bicyclist injuries based on the catchment area of a trauma centerDekeya R Slaughter, Nick Williams, Stephen P Wall, et al.
Cancer Research|August 26, 2024
Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast CancerMi Li, Amriti R Lulla, Yan Wang, et al.
Nature Communications|April 1, 2025
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATRHaineng Xu, Erin George, David Gallo, et al.
Nutrients|January 10, 2026
The Responsible Health AI Readiness and Maturity Index (RHAMI): Applications for a Global Narrative Review of Leading AI Use Cases in Public Health NutritionDominique J Monlezun, Gary Marshall, Lillian Omutoko, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Pageof 6